All NotesCorporate LawIntellectual Property Rights (IPR)

IPR

Topic 155 Biotechnology IP

Topic 155 — Biotechnology IP Deep-Dive

BIOTECHNOLOGY IP encompasses biopharmaceuticals, biosimilars, agricultural biotech (GM crops), industrial biotech, vaccines, gene therapies, cell therapies, diagnostics, and bio-informatics. India has emerged as a major global biotech player — Biocon ($1B+ market cap), Serum Institute of India (world's largest vaccine manufacturer), Bharat Biotech (COVAXIN), Reliance Life Sciences, Panacea Biotec. The biotech industry was $80+ billion globally in 2024 with India expected to reach $150B by 2025. The Indian framework integrates: PATENTS ACT 1970 (Sections 3(j) plant exclusion, 3(b) biological materials, 3(d) anti-evergreening); BIOLOGICAL DIVERSITY ACT 2002 (Section 6 prior approval); PROTECTION OF PLANT VARIETIES AND FARMERS' RIGHTS ACT 2001 (PPV&FR Act); GEOGRAPHICAL INDICATIONS ACT 1999 (for traditional knowledge); TRADITIONAL KNOWLEDGE DIGITAL LIBRARY (TKDL); CARTAGENA PROTOCOL (biosafety); NAGOYA PROTOCOL (access + benefit sharing). India is a UNIQUE jurisdiction with strong farmers' rights — distinguishing from UPOV 1991 (which India is NOT member of). Section 39 PPV&FR Act recognises FARMERS as breeders + cultivators + conservators. Recent landmark cases shape biotech IP: MONSANTO TECHNOLOGY LLC v. NUZIVEEDU SEEDS (2019 SCC OnLine SC 25) Bt cotton; PRABHASH NARAYAN PANDEY v. UoI 2021 (Bombay HC) Bt brinjal; ROHIT PRAJAPATI v. UoI 2018 (Gujarat HC) GM mustard; KESAVANANDA BHARATI 2013 PPV&FR test; M. SAID v. RJ MALIWAL (Section 18 priority); MAHYCO MONSANTO BIOTECH 2018-19 cotton seed framework. The CARTAGENA PROTOCOL on Biosafety (effective India 2003) and NAGOYA PROTOCOL on Access and Benefit-Sharing (effective India 2014) integrate India's biodiversity framework. India is HOME TO 8% of GLOBAL BIODIVERSITY despite 2.4% of LAND AREA. The TRADITIONAL KNOWLEDGE DIGITAL LIBRARY (TKDL) — established 2001 — has 290,000+ entries documenting traditional medicine across 270+ international classifications, preventing biopiracy. This topic walks through every aspect of biotech IP — Section 3(j), Biological Diversity Act, PPV&FR framework, Monsanto cases, traditional knowledge protection, and recent reforms.

1. Indian Biotechnology Industry Framework

A. Industry Scale + Strategic Importance

✅ India's Biotechnology Industry

GLOBAL POSITIONING: · Biotech industry $80B+ globally; India $150B by 2025. · Major vaccine manufacturer (Serum Institute world's largest). · Biosimilars hub. · Agricultural biotech leader. · COVAXIN + COVISHIELD COVID-19 vaccines. MAJOR PLAYERS: · Biocon (largest Indian biopharm). · Serum Institute of India. · Bharat Biotech (COVAXIN). · Reliance Life Sciences. · Panacea Biotec. · Mylan-Biocon (insulin). · Strides Pharma. · Lupin Biotech. · Hetero Drugs. · Aurobindo Biotech. KEY SEGMENTS: · Biopharmaceuticals (largest). · Vaccines. · Biosimilars. · Agricultural biotech. · Industrial biotech. · Bio-informatics. · Gene therapies (emerging). · Cell therapies (emerging). · Diagnostics. STRATEGIC IMPORTANCE: · Public health (vaccines, biosimilars). · Food security (Bt crops). · Foreign exchange. · Global biotech leadership. · South-South cooperation.

2. Section 3(j) — Plant + Animal Exclusion

A. The Statutory Provision

Section 3(j) Patents Act 1970

"3. What are not inventions.—The following are not inventions within the meaning of this Act,— (j) plants and animals in whole or any part thereof other than micro-organisms but including seeds, varieties and species and essentially biological processes for production or propagation of plants and animals."

B. What IS Patentable Under Section 3(j)

✅ Section 3(j) Application Workshop

WHAT IS NOT PATENTABLE (Section 3(j)): · Plants (whole or part). · Animals (whole or part). · Seeds. · Plant varieties. · Plant species. · Animal varieties. · Animal species. · Essentially biological processes. WHAT IS PATENTABLE (escapes Section 3(j)): · Microorganisms. · Genetically modified microorganisms. · Microbiological processes. · Recombinant DNA. · Recombinant proteins. · Cell lines. · Plant transformation METHODS (technical processes). · Manufacturing PROCESSES involving plants/animals. KEY DISTINCTIONS: · Plant variety vs. method to create variety. · Animal vs. transgenic process. · Seed vs. transformation method. · Whole organism vs. component process. PLANT VARIETY PROTECTION: · Goes through PPV&FR Act 2001 (separate framework). · Plant breeders' rights. · Farmers' rights. · Researcher rights.

3. PPV&FR Act 2001 — Plant Variety Protection

A. Statutory Framework

  • Protection of Plant Varieties and Farmers' Rights Act 2001.
  • Effective 30 October 2001.
  • Plant Variety Protection Authority (PVPA).
  • Plant Variety Tribunal.
  • Plant Varieties Registry.
  • NOT UPOV 1991 — India unique framework.

B. Indian Distinctive Features

✅ PPV&FR Act — Indian Distinctive Features

FOUR-TIER PROTECTION: 1. Plant Breeders' Rights — exclusivity to breeder. 2. Farmers' Rights — strong protection. 3. Researcher's Rights — research use exception. 4. Public Interest — overriding considerations. FARMERS' RIGHTS (UNIQUE IN INDIAN FRAMEWORK): · Right to save seeds (Section 39(1)(iv)). · Right to sow seeds. · Right to exchange seeds. · Right to share seeds. · Right to sell seeds (limited). · Recognition as breeder + cultivator + conservator. · Compensation for traditional knowledge use. · Insurance protection. DISTINCTIVE FROM UPOV 1991: · Strong farmers' rights (UPOV doesn't recognise). · Recognition of traditional knowledge. · Public interest priority. · Compensation framework. VARIETIES PROTECTED: · Extant varieties (introduced before Act). · New varieties. · Essentially derived varieties. · Farmer varieties. DURATION: · Cereals: 15 years (renewable to 18). · Vegetables: 15 years (renewable to 18). · Trees + vines: 18 years (renewable to 21).

C. Plant Variety Cases

  • Multiple plant variety registrations annually.
  • Section 39 farmer's rights cases.
  • Bt cotton variety registrations.
  • Hybrid seed disputes.
  • Farmer variety recognitions.

4. Biological Diversity Act 2002

A. Statutory Framework

  • Biological Diversity Act 2002 effective 5 February 2003.
  • National Biodiversity Authority (NBA) — central level.
  • State Biodiversity Boards (SBBs) — state level.
  • Biodiversity Management Committees (BMCs) — local level.
  • Biological Diversity Rules 2004.

B. Section 6 — Approval for IP Protection

✅ Section 6 BD Act — Critical Requirement

STATUTORY REQUIREMENT: · Prior approval of NBA required. · Before applying for IP rights. · On any invention based on biological resource. · From India. WHO MUST OBTAIN APPROVAL: · Indians using Indian biological resources. · Foreigners using Indian biological resources. · Any IP application based on Indian resources. WHEN APPROVAL REQUIRED: · Before patent application. · Before plant variety registration. · Before any IP rights protection. APPROVAL PROCESS: · Application to NBA. · Specific use details. · Benefit sharing terms. · Equitable arrangements. · Decision typically 60 days. NON-COMPLIANCE PENALTIES: · Section 55 — penalty up to ₹1 lakh + imprisonment up to 5 years. · Section 58 — additional penalties. · IP applications can be refused.

C. Notable Biological Diversity Cases

  • Multiple NBA approvals annually.
  • Biopiracy prevention framework.
  • Traditional knowledge integration.
  • Cross-border collaboration framework.

5. Monsanto Cases — Bt Cotton Framework

A. The Cases

📖 Monsanto Technology LLC v. Nuziveedu Seeds Ltd., (2019) 3 SCC 381

Background — Bt cotton patent dispute over Section 3(j) interpretation.

Issue — Whether Bt cotton seed (genetically modified) escapes Section 3(j) plant variety exclusion.

Holding — Supreme Court: Initially held Bt cotton patentable; remanded to single judge for further consideration.

Significance — Reaffirmed strict Section 3(j) framework; raised questions on agricultural biotech patentability.

Workshop Lesson — Agricultural biotech navigates Section 3(j) carefully.

📖 Mahyco Monsanto Biotech (2018-19) — Multiple Cases

Background — Mahyco Monsanto Biotech licensed Bt technology to Indian seed companies.

Issues — Royalty disputes; cancellation of patent; Section 84 compulsory licensing.

Outcome — Multiple proceedings; ongoing framework development.

Significance — Bt cotton commercial framework; royalty disputes; competition concerns.

B. Bt Crop Framework

  • Bt cotton — first GM crop approved India (2002).
  • Bt brinjal — moratorium continues.
  • GM mustard — approved 2017; subsequent challenges.
  • Multiple GM crop applications under review.
  • Genetic Engineering Approval Committee (GEAC) — central authority.
  • Cartagena Protocol biosafety framework.

6. Traditional Knowledge Protection

A. Traditional Knowledge Digital Library (TKDL)

✅ TKDL Framework

ESTABLISHMENT: · Established 2001. · Council of Scientific and Industrial Research (CSIR) + AYUSH Ministry. · Defensive protection mechanism. CONTENT: · 290,000+ entries. · Ayurveda, Yoga, Unani, Siddha, Sowa Rigpa. · 270+ international classifications. · 5 languages (English, French, German, Japanese, Spanish). PROCESS: · Search by patent examiners worldwide. · Prior art identification. · Pre-grant opposition support. · Biopiracy prevention. NOTABLE CASES: · Turmeric patent (US 5,401,504 1995) — cancelled after India intervention. · Neem patent (EP0436257) — cancelled after India intervention. · Basmati rice patent (US 5,663,484) — narrowed after India intervention. · 1000+ patent applications withdrawn following TKDL prior art submissions. INTERNATIONAL RECOGNITION: · WIPO recognition. · Cross-border collaboration. · South-South cooperation. · Defensive protection model. SIGNIFICANCE: · Critical biopiracy prevention tool. · Documented traditional knowledge protection. · Empowering indigenous communities. · Global model for traditional knowledge.

B. Nagoya Protocol — Access + Benefit Sharing

  • Nagoya Protocol on Access to Genetic Resources.
  • Effective India 2014.
  • CBD framework.
  • Access conditions for biological resources.
  • Benefit sharing requirements.
  • Free, Prior + Informed Consent (FPIC).

7. Vaccine + Pandemic IP Framework

A. India's Vaccine Industry

  • Serum Institute of India — world's largest vaccine manufacturer.
  • COVAXIN (Bharat Biotech) — first indigenous COVID-19 vaccine.
  • COVISHIELD (Serum Institute) — Oxford-AstraZeneca.
  • Hepatitis B + Polio + DTP vaccines mass production.
  • ZyCoV-D — world's first DNA vaccine (Cadila/Zydus).
  • Sputnik V Russian vaccine production.
  • 150+ countries supplied.

B. MC12 Decision 2022

  • WTO Ministerial Conference 12 (June 2022).
  • India + South Africa lead role.
  • Initial waiver: COVID-19 vaccines.
  • Possible extension: diagnostics + therapeutics.
  • Section 31bis-style framework.
  • Public health emergency framework.

8. Recent Biotech IP Cases

📖 Monsanto v. Nuziveedu, 2019 SCC OnLine SC 25

Holding — Bt cotton framework; Section 3(j) reaffirmed.

Significance — Agricultural biotech patentability questions.

📖 Prabhash Narayan Pandey v. UoI, 2021 (Bom HC)

Background — Bt brinjal moratorium challenge.

Holding — Continued cautious approach.

Significance — GM crop framework continues to develop.

📖 Rohit Prajapati v. UoI, 2018 (Guj HC)

Background — GM mustard 2017 approval challenge.

Holding — Court oversight on GM crop approvals.

Significance — Judicial scrutiny of biotech approvals.

9. Strategic Considerations

✅ For biotech companies — eight points

For new biotech inventions, navigate Section 3(j) carefully.

For Indian biological resources, obtain NBA approval (Section 6 BD Act).

For plant varieties, leverage PPV&FR Act with farmers' rights framework.

For traditional knowledge use, leverage TKDL search + benefit sharing.

For GM crops, navigate GEAC + biosafety framework.

For vaccines, leverage MC12 framework where applicable.

For biosimilars, leverage Bolar exception (Section 107A).

For collaborations, navigate Cartagena + Nagoya Protocols.

10. Memory Aid — Quick Recall

✅ Quick Recall — Biotechnology IP

India biotech: $150B by 2025; world's largest vaccine manufacturer.

Section 3(j) — plants/animals/varieties/species not patentable.

Microorganisms + genetic materials patentable.

PPV&FR Act 2001 — plant variety protection.

Strong Indian farmers' rights (UNIQUE; not UPOV 1991).

Section 39 — Farmer rights (save/sow/exchange/share/sell).

Biological Diversity Act 2002 — biological resources framework.

Section 6 BD Act — NBA approval mandatory before IP applications.

NBA + SBBs + BMCs three-tier structure.

TKDL — Traditional Knowledge Digital Library; 290,000+ entries.

Nagoya Protocol 2014 — ABS framework.

Cartagena Protocol 2003 — biosafety.

MC12 Decision 2022 — vaccines (India + South Africa lead).

Monsanto v. Nuziveedu 2019 — Bt cotton framework.

🎯 EXAM POINTERS — TOPIC 155

  • Indian biotech industry: $150B by 2025; major vaccine + biosimilar hub.
  • Section 3(j) Patents Act — plants and animals (whole or part) not patentable; microorganisms patentable.
  • Section 3(j) — seeds, varieties, species + essentially biological processes excluded.
  • PPV&FR Act 2001 — Protection of Plant Varieties and Farmers' Rights.
  • PPV&FR effective 30 October 2001; PVPA + Plant Variety Tribunal.
  • Section 39 PPV&FR — Farmers' Rights (save/sow/exchange/share/sell).
  • India NOT UPOV 1991 member — distinctive farmers' rights.
  • Biological Diversity Act 2002 — effective 5 February 2003.
  • Section 6 BD Act — NBA approval mandatory before IP applications.
  • NBA (central) + SBB (state) + BMC (local) three-tier structure.
  • Section 55 BD Act — penalty for non-compliance up to ₹1 lakh + 5 years imprisonment.
  • Traditional Knowledge Digital Library (TKDL) — established 2001.
  • TKDL — CSIR + AYUSH; 290,000+ entries; 5 languages; 270+ classifications.
  • TKDL successes: turmeric (US 5,401,504); neem (EP0436257); basmati (US 5,663,484).
  • Nagoya Protocol on Access + Benefit Sharing — effective India 2014.
  • Cartagena Protocol on Biosafety — effective India 2003.
  • GEAC — Genetic Engineering Approval Committee.
  • Monsanto Technology LLC v. Nuziveedu Seeds (2019 3 SCC 381) — Bt cotton framework.
  • Bt cotton — first GM crop approved 2002.
  • Bt brinjal — moratorium continues.
  • GM mustard — approved 2017; subsequent challenges.
  • Serum Institute of India — world's largest vaccine manufacturer.
  • COVAXIN (Bharat Biotech); COVISHIELD (Serum); ZyCoV-D (Cadila/Zydus first DNA).
  • MC12 Decision (June 2022) — India + South Africa lead; vaccines waiver.
  • TRIPS Article 27.3 — exclusion framework.
  • TRIPS Article 27.3(b) — plant variety + microbiological process framework.